Since there is a report that Compound A shows beneficial metabolic effects [10], we focused on whether the predominantly intestine-targeted DGAT1 inhibitor could improve obesity and insulin resistance without skin aberrations in mice in the present study. Here, DGAT1 is linked to Insulin resistance.